Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency
Authors:
- 10 December 2018
- journal article
- review article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (6) , 963-973
Abstract
Background: Quality of life (QoL) and health economic data are becoming increasingly important factors in healthcare decision-making. While there is a wealth of information establishing the benefit of growth hormone (GH) replacement therapy on adults with growth hormone deficiency (aGHD), recent reviews on the QoL and health economic impact of aGHD and the effect of treatment on these factors is limited. Objective: The aim of this article is to summarise the impact of early and sustained treatment on the QoL and economic burden of aGHD by conducting a targeted literature review. Methods: Standard electronic databases, including PubMed and the Cochrane collaboration website, were searched for publications between January 2006 and July 2016 for evidence of the humanistic and economic burden of aGHD. Search terms included growth hormone deficiency, health-related quality of life, HRQoL, patient-reported outcomes, outcome assessment, well-being and adherence. Results: The literature search identified 732 initial hits and a final 14 publications were included. The analysis showed that the economic burden of aGHD is largely driven by the productivity losses associated with the disease. This is because most patients with aGHD are of working age and the QoL domains (memory & concentration and energy & vitality) most commonly affected by aGHD severely impair a person’s ability to work and may limit their contribution to society. Conclusion: Untreated aGHD can seriously affect patient’s functioning. Early and continued treatment with GH replacement therapy could potentially improve the QoL and reduce the economic burden associated with the aGHD. This review has limitations; only English language articles published since January 2006 were included although many of the studies were conducted in the Nordic countries; it is unclear how representative these studies are of the population as a whole. This was a literature review and not a systematic review, as it was thought to be unlikely that in this rare disease, any additional publications would have been identified. Overall, this review reveals a paucity of data in this underserved population and points to research gaps which could be addressed with new studies.Keywords
This publication has 32 references indexed in Scilit:
- Fifteen years of GH replacement improves body composition and cardiovascular risk factorsEuropean Journal of Endocrinology, 2013
- Effects of Growth Hormone Replacement Therapy on Bone Mineral Density in Growth Hormone Deficient Adults: A Meta-AnalysisInternational Journal of Endocrinology, 2013
- Adult Growth Hormone Deficiency – Benefits, Side Effects, and Risks of Growth Hormone ReplacementFrontiers in Endocrinology, 2013
- Development and Validation of a New Questionnaire Assessing Quality of Life in Adults with Hypopituitarism: Adult Hypopituitarism Questionnaire (AHQ)PLOS ONE, 2012
- Adult growth hormone deficiencyIndian Journal of Endocrinology and Metabolism, 2011
- The effect of growth hormone (GH) replacement on muscle strength in patients with GH‐deficiency: a meta‐analysisClinical Endocrinology, 2010
- Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factorsLupus, 2009
- Cancer-Related Fatigue: The Scale of the ProblemThe Oncologist, 2007
- Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?European Journal of Endocrinology, 2006
- Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults – comparison between Sweden, The Netherlands and GermanyEuropean Journal of Endocrinology, 2006